Inactive Instrument

Highlights Dyadic International, Inc. Other OTC

Equities

US26745T1016

Highlights

Unlock all the news: Be the first to know and act before the market!

Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q1 Revenue $334.6M	15/05	MT
Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Dyadic Advances Collaboration with Israel Institute for Biological Research Targeting Bio-Threats and Emerging Disease Solutions	21/02	CI
Dyadic International Partners With Maravai LifeSciences' Cygnus Technologies Unit on HCP Assay	13/02	MT
Dyadic International Inc. and Cygnus Technologies Announce Partnership to Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing	13/02	CI
Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate	29/11	CI
Dyadic International Says C1 Platform Chosen for Vaccine Production in Africa	20/11	MT
Dyadic International, Inc. Announces its C1 Platform to Be Use to Produce Vaccines for Humans and Animals in Africa	20/11	CI
Dyadic International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Janssen Biotech, Inc. Terminates Research, License, and Collaboration Agreement with Dyadic International, Inc	07/23/07	CI
Dyadic International, Inc. Enters into Research Collaboration Agreement with Voltron Therapeutics, Inc	05/23/05	CI
Dyadic International, Inc. and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells	26/23/26	CI
Dyadic International, Inc. Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus?	19/23/19	CI
Dyadic International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q2 Revenue $837,159, vs. Street Est of $1.3M	10/23/10	MT
Dyadic Announces Positive Results from Third Party Analytical Testing of Animal-Free Recombinant Serum Albumin	07/23/07	CI
Dyadic International, Inc Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate	24/23/24	CI
Dyadic International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q1 Revenue $978,052	11/23/11	MT
Dyadic International, Inc. Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™	08/23/08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Dyadic International, Inc. Other OTC

Equities

US26745T1016

Highlights

Filters